Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $70.62 million. The enterprise value is -$14.97 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 61.95 million shares outstanding. The number of shares has increased by 38.73% in one year.
| Current Share Class | 61.95M |
| Shares Outstanding | 61.95M |
| Shares Change (YoY) | +38.73% |
| Shares Change (QoQ) | -0.32% |
| Owned by Insiders (%) | 6.29% |
| Owned by Institutions (%) | 32.25% |
| Float | 44.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.68 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.75, with a Debt / Equity ratio of 0.19.
| Current Ratio | 7.75 |
| Quick Ratio | 7.31 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.30% and return on invested capital (ROIC) is -31.70%.
| Return on Equity (ROE) | -66.30% |
| Return on Assets (ROA) | -29.19% |
| Return on Invested Capital (ROIC) | -31.70% |
| Return on Capital Employed (ROCE) | -68.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.16M |
| Employee Count | 44 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.16M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.85% in the last 52 weeks. The beta is 1.18, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -68.85% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 2.01 |
| Relative Strength Index (RSI) | 43.55 |
| Average Volume (20 Days) | 403,195 |
Short Selling Information
The latest short interest is 6.47 million, so 10.45% of the outstanding shares have been sold short.
| Short Interest | 6.47M |
| Short Previous Month | 7.05M |
| Short % of Shares Out | 10.45% |
| Short % of Float | 14.50% |
| Short Ratio (days to cover) | 14.49 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -83.16M |
| Pretax Income | -57.80M |
| Net Income | -95.23M |
| EBITDA | -80.75M |
| EBIT | -83.16M |
| Earnings Per Share (EPS) | -$1.56 |
Full Income StatementBalance Sheet
The company has $105.43 million in cash and $19.84 million in debt, giving a net cash position of $85.59 million or $1.38 per share.
| Cash & Cash Equivalents | 105.43M |
| Total Debt | 19.84M |
| Net Cash | 85.59M |
| Net Cash Per Share | $1.38 |
| Equity (Book Value) | 103.10M |
| Book Value Per Share | 1.67 |
| Working Capital | 97.44M |
Full Balance SheetCash Flow
| Operating Cash Flow | -59.50M |
| Capital Expenditures | n/a |
| Free Cash Flow | -59.50M |
| FCF Per Share | -$0.96 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.73% |
| Shareholder Yield | -38.73% |
| Earnings Yield | -134.85% |
| FCF Yield | -84.25% |
Analyst Forecast
The average price target for Pyxis Oncology is $9.00, which is 689.47% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 689.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 35.26% |
| EPS Growth Forecast (5Y) | -5.65% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pyxis Oncology has an Altman Z-Score of -1.88 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.88 |
| Piotroski F-Score | 1 |